{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:02:25Z","timestamp":1782853345210,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111837","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:06:41Z","timestamp":1782850001000},"source":"Crossref","is-referenced-by-count":0,"title":["Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Legionella Pneumonia"],"prefix":"10.7759","author":[{"given":"Alejandro","family":"Sanchez Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck DB","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, et al.. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020, 383:2628-38. 10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc2115847","article-title":"Case 2-2022: A 70-year-old man with a recurrent left pleural effusion","volume":"386","author":"Grayson PC","year":"2022","unstructured":"Grayson PC, Perugino CA, Dinculescu VV, Ferry JA. Case 2-2022: A 70-year-old man with a recurrent left pleural effusion. N Engl J Med. 2022, 386:274-83. 10.1056\/NEJMcpc2115847","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.08.003","article-title":"UBA1: At the crossroads of ubiquitin homeostasis and neurodegeneration","volume":"21","author":"Groen EJ","year":"2015","unstructured":"Groen EJ, Gillingwater TH. UBA1: At the crossroads of ubiquitin homeostasis and neurodegeneration. Trends Mol Med. 2015, 21:622-32. 10.1016\/j.molmed.2015.08.003","journal-title":"Trends Mol Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"15","author":"Kosmider O","year":"2024","unstructured":"Kosmider O, Poss\u00e9m\u00e9 C, Templ\u00e9 M, et al.. VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation. Nat Commun. 2024, 15:910. 10.1038\/s41467-024-44811-4","journal-title":"Nat Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck DB","year":"2023","unstructured":"Beck DB, Bodian DL, Shah V, et al.. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA. 2023, 329:318-24. 10.1001\/jama.2022.24836","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16635","article-title":"Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings","volume":"62","author":"Hines AS","year":"2023","unstructured":"Hines AS, Mohandesi NA, Lehman JS, et al.. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings. Int J Dermatol. 2023, 62:938-45. 10.1111\/ijd.16635","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqad186","article-title":"Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: a single-institution longitudinal study of 111 bone marrow samples from 52 patients","volume":"161","author":"Olteanu H","year":"2024","unstructured":"Olteanu H, Patnaik M, Koster MJ, et al.. Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: a single-institution longitudinal study of 111 bone marrow samples from 52 patients. Am J Clin Pathol. 2024, 161:609-24. 10.1093\/ajcp\/aqad186","journal-title":"Am J Clin Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022329","article-title":"Venous and arterial thrombosis in patients with VEXAS syndrome","volume":"143","author":"Kusne Y","year":"2024","unstructured":"Kusne Y, Ghorbanzadeh A, Dulau-Florea A, et al.. Venous and arterial thrombosis in patients with VEXAS syndrome. Blood. 2024, 143:2190-200. 10.1182\/blood.2023022329","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02164-6","article-title":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies","volume":"407","author":"Groarke EM","year":"2026","unstructured":"Groarke EM, Turturice B, Patel BA, Quinn KA, Fike A, Grayson PC. VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies. Lancet. 2026, 407:637-48. 10.1016\/S0140-6736(25)02164-6","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada MA","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO, et al.. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022, 140:1496-506. 10.1182\/blood.2022016985","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00225-5","article-title":"Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention","volume":"7","author":"Ribier V","year":"2025","unstructured":"Ribier V, Hadjadj J, Jachiet V, et al.. Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention. Lancet Rheumatol. 2025, 7:e734-44. 10.1016\/S2665-9913(25)00225-5","journal-title":"Lancet Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2022.494","article-title":"Treatment options for VEXAS syndrome","volume":"2","author":"Goring S","year":"2022","unstructured":"Goring S, Horton J. Treatment options for VEXAS syndrome. Can J Health Technol. 2022, 2:10.51731\/cjht.2022.494","journal-title":"Can J Health Technol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2023.01020","article-title":"VEXAS syndrome: current clinical, diagnostic and treatment approaches","volume":"12","author":"Kobak S","year":"2023","unstructured":"Kobak S. VEXAS syndrome: current clinical, diagnostic and treatment approaches. Intractable Rare Dis Res. 2023, 12:170-9. 10.5582\/irdr.2023.01020","journal-title":"Intractable Rare Dis Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172936","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: a systematic review and meta-analysis","volume":"142","author":"Shahzad M","year":"2023","unstructured":"Shahzad M, Khalid MF, Abbas S, et al.. Outcomes of allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: a systematic review and meta-analysis. Blood. 2023, 142:7085. 10.1182\/blood-2023-172936","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet V","year":"2025","unstructured":"Jachiet V, Kosmider O, Beydon M, et al.. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood. 2025, 146:1450-61. 10.1182\/blood.2024028133","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484936-newly-diagnosed-vexas-vacuoles-e1-enzyme-x-linked-autoinflammatory-somatic-syndrome-in-a-patient-presenting-with-legionella-pneumonia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:06:41Z","timestamp":1782850001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484936-newly-diagnosed-vexas-vacuoles-e1-enzyme-x-linked-autoinflammatory-somatic-syndrome-in-a-patient-presenting-with-legionella-pneumonia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.111837","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}